Heart failure & cardiomyopathies
Bromocriptine for Myocardial Recovery in Peripartum Cardiomyopathy: Design and Rationale of the REBIRTH Trial
Study context
- Population
- Women ≥18 years of age with peripartum cardiomyopathy (PPCM), within 5-months postpartum, with left ventricular ejection fraction (LVEF) ≤40%planned enrollment in the randomized trial, a further 50 women excluded from randomization because of breastfeeding to be enrolled in an observational cohort · randomized trial (planned) 200 · observational breastfeeding cohort (planned) 50
- Participants
- 200 women
- Planned comparison
- Addition of oral bromocriptine to guideline-directed medical therapy (GDMT) vs placebo
- Observational breastfeeding cohortn = 50
- Primary endpoint
- LVEF
- Follow-up
- 6 months postrandomization
Methodological detailsplacebo-controlled, on top of guideline-directed medical therapy (GDMT), observational breastfeeding cohort alongside the randomized trial, North America
- Placebo-controlled
- On top of guideline-directed medical therapy (GDMT)
- Observational breastfeeding cohort alongside the randomized trial
- North America
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Study conduct
- Primary results expected to be reported
- 2027
- Currently enrolling women in both the randomized trial and observational breastfeeding cohort
Original publication
Bromocriptine for Myocardial Recovery in Peripartum Cardiomyopathy: Design and Rationale of the REBIRTH Trial. JACC Heart Fail. Published 21 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →